Details for New Drug Application (NDA): 218709
✉ Email this page to a colleague
The generic ingredient in XOLREMDI is mavorixafor. One supplier is listed for this compound. Additional details are available on the mavorixafor profile page.
Summary for 218709
Tradename: | XOLREMDI |
Applicant: | X4 Pharms |
Ingredient: | mavorixafor |
Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 218709
Generic Entry Date for 218709*:
Constraining patent/regulatory exclusivity:
TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS) Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 218709
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709 | NDA | X4 Pharmaceuticals, Inc. | 83296-100 | 83296-100-12 | 120 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-12) |
XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709 | NDA | X4 Pharmaceuticals, Inc. | 83296-100 | 83296-100-60 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 100MG | ||||
Approval Date: | Apr 26, 2024 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Apr 26, 2029 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Regulatory Exclusivity Expiration: | Apr 26, 2031 | ||||||||
Regulatory Exclusivity Use: | TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS) | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 11, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription